Biomea Fusion, Inc. has announced a strategic realignment to focus on its core programs in diabetes and obesity, specifically advancing icovamenib and BMF-650, while cutting costs to extend its cash ...
MAKING ANY MAJOR DIETARY CHANGES. THE WHITE HOUSE ANNOUNCING THIS WEEK A NEW DEAL TO MAKE WEIGHT LOSS MEDICATIONS SUCH AS WEGOVY AND ZEPBOUND MORE AFFORDABLE FOR MILLIONS OF AMERICANS. SO JOINING US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback